Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study
Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine.
“These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies,” said Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study’s senior authors. “Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer.”
Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy. Without a successful bone marrow transplant, few have any hope of long-term survival.
In the current study, 16 patients with relapsed B-ALL were given an infusion of their own genetically modified immune cells, called T cells. The cells were “reeducated” to recognize and destroy cancer cells that contain the protein CD19. While the overall complete response rate for all patients was 88 percent, even those with detectable disease prior to treatment had a complete response rate of 78 percent, far exceeding the complete response rate of salvage chemotherapy alone.
Dennis J. Billy, C.Ss.R, of Wynnewood, Pennsylvania, was one of the first patients to receive this treatment more than two years ago. He was able to successfully undergo a bone marrow transplant and has been cancer-free and back at work teaching theology since 2011. Paolo Cavalli, a restaurant owner from Oxford, Connecticut, remains in complete remission eight months after receiving his personalized T cell treatment.
A History of Scientific Achievements for Cell-Based Therapies
Cell-based, targeted immunotherapy is a new approach to treating cancer that harnesses the body’s own immune system to attack and kill cancerous cells. Unlike with a common virus such as the flu, our immune system does not recognize cancer cells as foreign and is therefore at a disadvantage in eradicating the disease. For more than a decade, researchers at Memorial Sloan Kettering have been exploring ways to reengineer the body’s own T cells to recognize and attack cancer. In 2003, they were the first to report that T cells engineered to recognize the protein CD19, which is found on B cells, could be used to treat B cell cancers in mice.
“Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients,” said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study’s senior authors. “It’s extremely gratifying to witness the astonishing results firsthand in my patients, having worked for more than a decade developing this technology from the ground up.”
In March 2013, the same team of researchers first reported the results of five patients with advanced B-ALL who were treated with cell therapy. Remarkably, all five patients achieved complete remissions.
Results Demonstrate Potential of New Therapy
In the current study, seven of the 16 patients (44 percent) were able to successfully undergo bone marrow transplantation — the standard of care and the only curative option for B-ALL patients — following treatment. Three patients were ineligible due to failure to achieve a complete remission, three were ineligible due to preexisting medical conditions, two declined, and one is still being evaluated for a potential bone marrow transplant. Historically, only 5 percent of patients with relapsed B-ALL have been able to transition to bone marrow transplantation.
The Latest on: Cell therapy
[google_news title=”” keyword=”Cell therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cell therapy
- Celebrities Quietly Paying Huge Amounts for Anti-Aging Stem Cell Therapy That May Cause Gruesome Side Effectson April 27, 2024 at 6:31 am
Experts caution that there's limited evidence backing the benefits of these stem cell treatments, while pointing to plenty of risks.
- Bristol Myers Squibb closes immuno-oncology, cell therapy-focused Redwood City siteon April 26, 2024 at 7:59 am
One of Chris Boerner’s first tours as the new CEO of Bristol Myers Squibb was of a 256,000 square-foot research facility in the Bay Area concentrated on the tumor microenvironment. | Bristol Myers ...
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohorton April 25, 2024 at 6:55 am
(NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary ...
- John Cleese is spending thousands on stem cell therapy – is it really the secret to anti-ageing?on April 24, 2024 at 10:00 pm
John Cleese is spending thousands on stem cell therapy – is it really the secret to anti-ageing? - IN FOCUS: ‘Monty Python’ star John Cleese has revealed that he has been having stem cell treatment ...
- The murky, unregulated world of anti-ageing stem cell therapyon April 24, 2024 at 10:50 am
Stem cells are the new focal point of the rich and famous with Hollywood A-listers reportedly spending tens of thousands of pounds each year on expensive therapies offered by private longevity clinics ...
- CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in clinical trialon April 24, 2024 at 5:32 am
Researchers at Texas Children's Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist have published results of a Phase ...
- John Cleese says he’s been spending £17,000 annually on stem cell therapy to ‘buy a few extra years’on April 24, 2024 at 1:01 am
John Cleese says he’s been spending £17,000 annually on stem cell therapy to ‘buy a few extra years’ - ‘I think that’s why I don’t look bad for 84,’ the ‘Fawlty Towers’ star said ...
- Cell Therapy Startup Energized via Smarter Operationson April 23, 2024 at 5:00 pm
A British-based cell therapy company is using smart operations to streamline its viral vector processing. According to Paul S. Carter, senior director, manufacturing science and technology (MSAT), at ...
- With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer Cellareson April 22, 2024 at 8:10 am
Bristol Myers Squibb was the first major biopharma company to take notice of innovative cell therapy contract manufacturer Cellares, participating to a $255 million series C funding round in August | ...
- Review Finds Anti-BCMA CAR T-Cell Therapy Effective in Patients With MMon April 22, 2024 at 7:11 am
A new meta-analysis of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma (MM) suggests the treatment has a strong rate of efficacy and that adverse events (AEs) ...
via Bing News